Bioversys AG has joined the EU-funded RespiriNTM program that is exploring multiple approaches to determine new targets for antimycobacterial compounds, define and optimize novel inhibitors and advance these through the process of hit-to-lead up until first-in-human trials.
Researchers from Kexing Biopharm Co. Ltd. have published details on the development and preclinical characterization of GB18-06, a novel nanobody, also known as variable domain of heavy-chain antibody (VHH), targeting growth differentiation factor 15 (GDF15) and being developed for the treatment of cachexia.
Repeated RNA elements have a virus-like behavior in the cells that express them. Furthermore, they could confer a novel mode of tumor expansion based on changes in cellular states. “About 10 years ago, we had identified that these repetitive elements were highly expressed in pancreas cancer,” co-senior author David Ting, associate professor of medicine and assistant physician at the Mass General Cancer Center at Harvard Medical School, told BioWorld.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed new GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Work at Janssen Pharmaceutica NV has led to the identification of lactam-containing imidazopyridazine interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction inhibitors.
The University of Virginia and Virginia Tech Intellectual Properties Inc. have patented protein spinster homolog 2 (SPNS2) inhibitors reported to be useful for the treatment of asthma, multiple sclerosis, chronic kidney disease and metastatic cancer.
Caraway Therapeutics Inc. patents describe new mucolipin (MCOLN; TRPML) activators reported to be useful for the treatment of aging, cancer, ciliopathies, glycogen and lysosomal storage diseases, macular degeneration, neurodegeneration and autosomal dominant polycystic kidney.
Glutamate oxaloacetate transaminase (GOT) is a glutamate scavenger that has been proposed to be used to counteract the excitotoxicity secondary to stroke or traumatic brain injury, among other pathologies. Furthermore, recent research suggests that mitochondrial GOT protects against energy failure after ischemia.
RSS
